Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OXFD

Oxford Immunotec Global (OXFD) Stock Price, News & Analysis

Oxford Immunotec Global logo

About Oxford Immunotec Global Stock (NASDAQ:OXFD)

Advanced Chart

Key Stats

Today's Range
$21.99
$21.99
50-Day Range
$21.88
$21.99
52-Week Range
$8.37
$23.11
Volume
N/A
Average Volume
1.10 million shs
Market Capitalization
$570.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Receive OXFD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Immunotec Global and its competitors with MarketBeat's FREE daily newsletter.

OXFD Stock News Headlines

A Game-Changing Vaccine
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Nigeria rolls out new Oxford R21 malaria vaccine
See More Headlines

OXFD Stock Analysis - Frequently Asked Questions

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The firm earned $19.44 million during the quarter, compared to analyst estimates of $18.58 million. Oxford Immunotec Global had a negative net margin of 30.51% and a negative trailing twelve-month return on equity of 8.39%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Immunotec Global investors own include Intel (INTC), Gilead Sciences (GILD), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Gold Resource (GORO).

Company Calendar

Last Earnings
11/03/2020
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
NASDAQ:OXFD
Fax
N/A
Employees
273
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.81 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$73.71 million
Cash Flow
$0.02 per share
Price / Cash Flow
1,408.78
Book Value
$8.08 per share
Price / Book
2.72

Miscellaneous

Free Float
N/A
Market Cap
$570.90 million
Optionable
Not Optionable
Beta
1.42
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:OXFD) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners